Lineage Cell Therapeutics (United States)

Lineage Cell Therapeutics (United States)

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Lineage Cell Therapeutics (United States), United States, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

60%


Total
Publications

152


Total Open
Publications

91


Total
Citations

6.1K


Open Access
Percentage

60%


Total
Publications

152


Total Open
Publications

91


Total
Citations

6.1K

Wikipedia

Website

download

Breakdown

16% 32% 12% 40%

Publisher Open

16%

Both

32%

Other Platform Open

12%

Closed

40%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

01234567891011121314Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

30%OA Journal

OA Journal 30%

22

Hybrid 35%

25

No Guarantees 35%

25

Other Platform Open

Domain 96%

64

Institution 19%

13

Public 18%

12

Other Internet 6%

4

Preprint 3%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
63
Europe PMC
Domain
55
Semantic Scholar
Public
12
University of Southern Denmark - University of Southern Denmark Research Portal
Institution
4
University of California - eScholarship University of California
Institution
3
University of Oslo - Duo Research Archive
Institution
2
University College London - UCL Discovery
Institution
2
DOI
Other Internet
2
bioRxiv
Preprint
2
wustl.edu OAI-PMH Repository
Institution
1
1 / 3

Data updated 25 January 2024

Share

Share

Share